Mission Pharmacal Company announced today that it is developing a new drug delivery system utilizing technology developed by TriLogic Pharma. The delivery system will be based upon TriLogic's proprietary drug delivery platform TRI-726 and will be licensed to Mission Pharmacal for future drug development.
"Mission Pharmacal's growth over the last 60 years has been the result of good relationships with other innovative pharmaceutical companies. We look forward to working with TriLogic and its new technology," stated Terry Herring, president of Mission Pharmacal's Commercial Operations.
Jim Harwick, president of TriLogic Pharma, said, "We are excited to partner with Mission Pharmacal on the development of a new drug delivery system. We continue to be pleased with the versatility of TRI-726 and the wide range of therapeutic classes and actives that can be developed with our novel delivery platform."